Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
CAPS Rating:
A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options.
RSS Headlines
Fool UK
Recs
The company has a strong pipeline of drugs, keeps getting approvals from the FDA, and has been building strong networks with physicians (prevents generics from taking back that much market share). Also, it has been said that Spectrum has only tapped roughly 50% of the possible physicians to date.